ES2421405T3 - Composiciones que comprenden un agonista del receptor de glucocorticoides disociado para tratar o controlar una inflamación del segmento anterior - Google Patents

Composiciones que comprenden un agonista del receptor de glucocorticoides disociado para tratar o controlar una inflamación del segmento anterior

Info

Publication number
ES2421405T3
ES2421405T3 ES08797177T ES08797177T ES2421405T3 ES 2421405 T3 ES2421405 T3 ES 2421405T3 ES 08797177 T ES08797177 T ES 08797177T ES 08797177 T ES08797177 T ES 08797177T ES 2421405 T3 ES2421405 T3 ES 2421405T3
Authority
ES
Spain
Prior art keywords
group
inflammation
substituted
receptor agonist
anterior segment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08797177T
Other languages
English (en)
Inventor
Keith Wayne Ward
Claudio Bucolo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bausch and Lomb Inc
Original Assignee
Bausch and Lomb Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch and Lomb Inc filed Critical Bausch and Lomb Inc
Application granted granted Critical
Publication of ES2421405T3 publication Critical patent/ES2421405T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Una composición para su uso en el tratamiento o control post-operatorio de la inflamación ocular del segmentoanterior de un ojo, resultando dicha inflamación de un procedimiento seleccionado entre el grupo que consiste enqueratectomía fotorrefractiva, cirugía de eliminación de cataratas, implante de lente intraocular ("IOL"),queratomilieusis in situ asistida por láser ("LASIK"), queratoplastia conductiva, y queratotomía radial; comprendiendodicha composición un agonista del receptor de glucocortidoides disociado ("DIGRA"), o una sal del mismofarmacéuticamente aceptable; donde el DIGRA comprende un compuesto que tiene la Fórmula I**Fórmula** donde A comprende un grupo dihidrobenzofuranilo sustituido con un átomo de halógeno; Q comprende un grupoquinolinilo o isoquinolinilo sustituido con un grupo alquilo C1-C10; R1 y R2 se seleccionan independientemente entre elgrupo que consiste en grupos alquilo C1-C5 sin sustituir o sustituido; B es un grupo alquileno C1-C3; D es el grupo -NH-; E es el grupo hidroxi; y R3 comprende un grupo alquilo C1-C10 completamente halogenado.
ES08797177T 2007-08-10 2008-08-05 Composiciones que comprenden un agonista del receptor de glucocorticoides disociado para tratar o controlar una inflamación del segmento anterior Active ES2421405T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95504407P 2007-08-10 2007-08-10
PCT/US2008/072201 WO2009023471A2 (en) 2007-08-10 2008-08-05 Compositions comprising a dissociated glucocorticoid receptor agonist for treating or controlling anterior-segment inflammation

Publications (1)

Publication Number Publication Date
ES2421405T3 true ES2421405T3 (es) 2013-09-02

Family

ID=40263555

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08797177T Active ES2421405T3 (es) 2007-08-10 2008-08-05 Composiciones que comprenden un agonista del receptor de glucocorticoides disociado para tratar o controlar una inflamación del segmento anterior

Country Status (19)

Country Link
US (1) US20090042936A1 (es)
EP (1) EP2190431B1 (es)
JP (1) JP5209718B2 (es)
KR (2) KR101298826B1 (es)
CN (1) CN101969950A (es)
AU (1) AU2008287142B2 (es)
BR (1) BRPI0815130A2 (es)
CA (1) CA2694227C (es)
CY (1) CY1114480T1 (es)
DK (1) DK2190431T3 (es)
ES (1) ES2421405T3 (es)
HK (1) HK1141249A1 (es)
HR (1) HRP20130631T1 (es)
MX (1) MX2010001370A (es)
PL (1) PL2190431T3 (es)
PT (1) PT2190431E (es)
SI (1) SI2190431T1 (es)
TW (1) TWI410252B (es)
WO (1) WO2009023471A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110077270A1 (en) * 2009-04-21 2011-03-31 Pfeffer Bruce A Compositions and Methods for Treating Ocular Inflammation with Lower Risk of Increased Intraocular Pressure
US10278810B2 (en) * 2010-04-29 2019-05-07 Ojo, Llc Injectable physiologically adaptive intraocular lenses (IOL's)
US20120316199A1 (en) * 2011-06-07 2012-12-13 Ward Keith W Compositions and methods for treating, controlling, reducing, or ameliorating inflammatory pain
MX361886B (es) * 2012-05-08 2018-12-18 Nicox Ophthalmics Inc Preparaciones de agentes terapéuticos hidrófobos, métodos de elaboración y uso de los mismos.
KR20210119980A (ko) 2019-01-22 2021-10-06 아크리베스 바이오메디컬 게엠베하 손상된 피부 상처를 치료하기 위한 선택적 글루코코르티코이드 수용체 개질제
WO2020215084A1 (en) * 2019-04-18 2020-10-22 Teeny Clean, Llc Device and method for stimulating the meibomian glands of the eyelid

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2613139B2 (ja) * 1990-07-19 1997-05-21 エスエス製薬 株式会社 キノロンカルボン酸誘導体
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US6051576A (en) * 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6242196B1 (en) * 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
AU4713499A (en) * 1998-06-27 2000-01-17 Photogenesis, Inc. Ophthalmic uses of ppargamma agonists and ppargamma antagonists
AU6275999A (en) * 1998-09-30 2000-04-17 Alcon Laboratories, Inc. Antibiotic compositions for treatment of the eye, ear and nose
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
AU2003202216A1 (en) * 2002-01-14 2003-07-30 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof
EP1490317A1 (en) * 2002-03-26 2004-12-29 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DK1490062T3 (da) * 2002-03-26 2008-04-28 Boehringer Ingelheim Pharma Glukokortikoidmimetika, fremgangsmåder til fremstilling deraf, farmaceutiske sammensætninger og anvendelser deraf
US6897224B2 (en) * 2002-04-02 2005-05-24 Schering Ag Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors
US7074806B2 (en) * 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
EP1521733B1 (en) * 2002-07-08 2014-08-20 Pfizer Products Inc. Modulators of the glucocorticoid receptor
WO2004063163A1 (en) * 2003-01-03 2004-07-29 Boehringer Ingelheim Pharmaceuticals, Inc. 1-propanol and 1-propylamine derivatives and their use as glucocorticoid ligands
US20040224992A1 (en) * 2003-02-27 2004-11-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2004097410A1 (en) * 2003-04-30 2004-11-11 Pfizer Products Inc. Screening methods for cataractogenic risk
UY28526A1 (es) * 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
US7795272B2 (en) * 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
JP2007530541A (ja) * 2004-03-22 2007-11-01 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメチックスとしてのα−トリフルオロメチルアルコール又はアミン
DE102004055633A1 (de) * 2004-11-12 2006-05-18 Schering Ag 5-substituierte Chinolin- und Isochinolin-Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
US7417056B2 (en) * 2004-11-12 2008-08-26 Schering Ag 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents
JP2008525525A (ja) * 2004-12-27 2008-07-17 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメティクス、その製法、医薬組成物及び使用
CA2621292C (en) * 2005-09-14 2014-05-27 Santen Pharmaceutical Co., Ltd. 1-2-dihydroquinoline derivative having glucocorticoid receptor binding actvity
BRPI0714817A2 (pt) * 2006-08-07 2013-05-21 Bausch & Lomb composiÇço, mÉtodo para tratar, reduzir, melhorar ou aliviar um condiÇço ou distérbio da parte posterior dos olhos, uso de um digra, e, mÉtodo para fabricar uma composiÇço
AU2007284175A1 (en) * 2006-08-07 2008-02-21 Bausch & Lomb Incorporated Treating infections and sequelae thereof with combined dissociated' glucocorticoid receptor agonists and anti-infective agents
CA2661607C (en) * 2006-08-31 2012-06-26 Bausch & Lomb Incorporated Compositions and methods for treating or preventing glaucoma or progression thereof
PL2151436T3 (pl) * 2007-05-29 2013-09-30 Santen Pharmaceutical Co Ltd Nowe pochodne 1,2,3,4-tetrahydrochinoksaliny, które jako podstawnik zawierają grupę fenylową z wprowadzoną strukturą estru kwasu sulfonowego lub amidu kwasu sulfonowego i które mają aktywność wiążącą wobec receptora glukokortykoidowego
WO2008154129A1 (en) * 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye

Also Published As

Publication number Publication date
EP2190431A2 (en) 2010-06-02
PT2190431E (pt) 2013-10-09
DK2190431T3 (da) 2013-09-08
CA2694227A1 (en) 2009-02-19
MX2010001370A (es) 2010-03-01
SI2190431T1 (sl) 2013-10-30
KR101298826B1 (ko) 2013-08-27
CA2694227C (en) 2012-07-03
CY1114480T1 (el) 2016-10-05
JP2010535796A (ja) 2010-11-25
CN101969950A (zh) 2011-02-09
WO2009023471A2 (en) 2009-02-19
PL2190431T3 (pl) 2013-11-29
HRP20130631T1 (hr) 2013-08-31
AU2008287142A1 (en) 2009-02-19
TWI410252B (zh) 2013-10-01
AU2008287142B2 (en) 2012-02-02
JP5209718B2 (ja) 2013-06-12
TW200911286A (en) 2009-03-16
BRPI0815130A2 (pt) 2017-05-09
EP2190431B1 (en) 2013-07-03
HK1141249A1 (en) 2010-11-05
US20090042936A1 (en) 2009-02-12
KR20120113802A (ko) 2012-10-15
KR20100029851A (ko) 2010-03-17
WO2009023471A3 (en) 2009-06-25

Similar Documents

Publication Publication Date Title
ES2421405T3 (es) Composiciones que comprenden un agonista del receptor de glucocorticoides disociado para tratar o controlar una inflamación del segmento anterior
Yoo et al. Femtosecond laser–assisted sutureless anterior lamellar keratoplasty
Mai et al. Oral mucosal grafts: old technique in new light
WO2010059214A3 (en) Biocompatible biodegradable intraocular implant system
Tahzib et al. Recurrent intraocular inflammation after implantation of the Artiflex phakic intraocular lens for the correction of high myopia
Takiyama et al. In‐body tissue‐engineered collagenous connective tissue membranes (BIOSHEETs) for potential corneal stromal substitution
Robert et al. Collagen cross-linking of the Boston keratoprosthesis donor carrier to prevent corneal melting in high-risk patients
RU2499582C1 (ru) Способ лазерного лечения первичной открытоугольной глаукомы с узким углом передней камеры
Huang et al. Anterior lens capsule: biomechanical properties and biomedical engineering perspectives
KR20130058608A (ko) 안과 질환의 예방 및 치료용 약학 조성물
Abdelwahab et al. After-cataract evaluation after using balanced salt solution, distilled deionized water, and 5-fluorouracil with a sealed-capsule irrigation device in the eyes of 4-week-old rabbits
AR044720A1 (es) Una sulfonamida heterociclica, su uso, un proceso para prepararla, una composicion farmaceutica que la comprende, y compuestos utiles como intermediari0s
NZ518816A (en) Substituted homopiperidinyl benzimidazole analogues useful as fundic relaxants
MD656Z (ro) Metodă de tratament al cataractei senile
RU2642731C1 (ru) Способ хирургического лечения открытоугольной глаукомы у пациентов с артифакией
You et al. Effect of corticosteroids on rabbit corneal keratocytes after photorefractive keratectomy
RU2698445C1 (ru) Способ хирургического лечения птеригиума 3 - 5 степени
AR115991A1 (es) EL USO DE AGONISTAS DE LOS RECEPTORES a2 ADRENÉRGICOS PARA MEJORAR LA VISIÓN
ATE227135T1 (de) Miotische wirkstoffe und hypertonische wirkstoffe enthaltende ophthalmische zusammensetzungen
Bao et al. Effect of an MG132-sustained drug delivery capsular ring on the inhibition of posterior capsule opacification in a rabbit model
Kyoung et al. The clinical effect of micro-multiporous expanded polytetrafluoroethylene insertion for recurrent pterygium
RU2013111281A (ru) Агонисты ер2 или ер4 для лечения помутнения роговицы
Sharma et al. Trypan-blue-assisted posterior capsule plaque removal
US20100136024A1 (en) Selective Inhibition of Histone Deacetylase 6 for Ocular Neuroprotection or for Treatment or Control of Glaucoma
Ibrahim et al. The role of iris color in femtosecond laser-induced miosis in patients undergoing cataract surgery